Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting

BACKGROUND: To compare the benefits and explore the cause of acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and its combination with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients harboring EGFR mutation in a real-life setting. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qianqian, Gao, Wen, Gao, Fangyan, Jin, Shidai, Qu, Tianyu, Lin, Fan, Zhang, Chen, Zhang, Jingya, Zhang, Zhihong, Chen, Liang, Guo, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152122/
https://www.ncbi.nlm.nih.gov/pubmed/34034713
http://dx.doi.org/10.1186/s12885-021-08291-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152122/
https://www.ncbi.nlm.nih.gov/pubmed/34034713
http://dx.doi.org/10.1186/s12885-021-08291-9

Ejemplares similares